In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | N/A | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A | |
2011 | N/A | |
2010 | N/A | |
2009 | N/A | |
2005 | $0.57 M | -3.37% |
2004 | $0.59 M | 151.61% |
2003 | $0.23 M | 54.1% |
2002 | $0.15 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Eli Lilly LLY | $35.93 B | N/A | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | N/A | ๐บ๐ธ USA |
Mirati Therapeutics MRTX | $38.19 M | N/A | ๐บ๐ธ USA |
Aeterna Zentaris AEZS | $4.49 M | N/A | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $15.84 B | N/A | ๐ฎ๐ฑ Israel |
AVEO Oncology
AVEO | $94.31 M | N/A | ๐บ๐ธ USA |